Country for PR: United Kingdom
Contributor: PR Newswire Europe
Wednesday, May 13 2020 - 20:43
Cipla Enters Into a Licensing Agreement With Gilead to Expand Access to COVID-19 Treatment
MUMBAI, India, May 13, 2020 /PRNewswire-AsiaNet/ --

Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (and hereafter referred to as 
"Cipla") today announced that it has signed a non-exclusive licensing agreement 
with Gilead Sciences, Inc. for the manufacturing and distribution of the 
investigational medicine Remdesivir, which has been issued an Emergency Use 
Authorization (EUA) by the U.S. Food and Drug Administration (FDA) to treat 
COVID-19 patients. This agreement is part of Cipla's efforts to enhance global 
access to life-saving treatments for patients affected by the pandemic.

As part of the agreement, Cipla will be permitted to manufacture the API and 
Finished product, and market it in 127 countries including India and South 
Africa under Cipla's own brand name. Cipla will receive the manufacturing 
know-how from Gilead Sciences, Inc. to manufacture the API and Finished product 
at a commercial scale. Cipla's extensive geographical and commercial footprint 
will help make this therapy accessible to more patients and markets.  

According to the World Health Organisation (WHO)'s tracker, the number of 
reported COVID-19 cases has crossed the four million mark globally. 

The EUA will facilitate broader use of Remdesivir to treat hospitalized 
patients with severe symptoms of COVID-19. The EUA is based on available data 
from two global clinical trials – US National Institute for Allergy and 
Infectious Diseases' placebo-controlled Phase 3 study in patients with moderate 
to severe symptoms of COVID-19, and Gilead's global Phase 3 study evaluating 
Remdesivir in patients with severe disease. Multiple additional clinical trials 
are ongoing to generate more data on the safety and efficacy of Remdesivir as a 
potential treatment for COVID-19. Remdesivir continues to be an investigational 
drug that has not been approved by the FDA. 

Commenting on the partnership, Mr. Umang Vohra (MD and Global CEO, Cipla 
Limited) said, "As the world is faced with the COVID-19 crisis, it is 
imperative that we collaborate and fight this virus together. We are pleased to 
partner with Gilead for this cause and take this treatment to patients across 
countries after the required regulatory approvals. At Cipla, it is our 
continuous endeavour to ensure that no patient is denied access to life-saving 
treatments. Our partnership with Gilead represents this unwavering commitment 
and is a significant step towards saving millions of lives impacted by the 

About Cipla:  

Established in 1935, Cipla is a global pharmaceutical company focused on agile 
and sustainable growth, complex generics, and deepening portfolio in our home 
markets of India, South Africa, North America, and key regulated and emerging 
markets. Our strengths in the respiratory, anti-retroviral, urology, 
cardiology, anti-infective and CNS segments are well-known. Our 46 
manufacturing sites around the world produce 50+ dosage forms and 1,500+ 
products using cutting-edge technology platforms to cater to our 80+ markets. 
Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Mar'20), 3rd largest 
in the pharma private market in South Africa (IQVIA MAT Mar'20), and is among 
the most dispensed generic players in the U.S. For over eight decades, making a 
difference to patients has inspired every aspect of Cipla's work. Our 
paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less 
than a dollar a day in Africa in 2001 is widely acknowledged as having 
contributed to bringing inclusiveness, accessibility and affordability to the 
centre of the HIV movement. A responsible corporate citizen, Cipla's 
humanitarian approach to healthcare in pursuit of its purpose of 'Caring for 
Life' and deep-rooted community links wherever it is present make it a partner 
of choice to global health bodies, peers and all stakeholders. For more, please 
visit, or click on Twitter [], 
Facebook [], LinkedIn 


Source: Cipla